Skip to content
DeepViews

Standard BioTools Inc. Common Stock (LAB) — 分析摘要

Standard BioTools Inc. Common Stock(LAB)的市值为270.64百万美元,最近一年的营收同比增长了-51.1%。净利润率为-87.8%。当前市盈率为3.2倍。

核心要点

  • 营收同比变化-51.1%
  • 净利润率-87.8%
  • 市盈率3.2倍

与PHARMACEUTICAL PREPARATIONS板块的其他公司相比,LAB的营收增长为-51.1%,市盈率为3.2倍。

[XNAS]

Standard BioTools Inc. Common Stock (LAB)

$0.66

前收盘价 2026-10-12 · 市场数据 POLYGON · 财务数据 SEC EDGAR

市值
$270.64M
企业价值
$-206.08M
市盈率
3.2
股息率
0.00%
EV/EBITDA
2.3
公司简介
关于
关于 Standard BioTools Inc. Common Stock

Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. The company operates in one segment. Its technology includes: Genomics; Single-cell proteomics; Spatial proteomics. Its platforms include: Biomark X9 System, CyTOF XT system, and Hyperion XTi Imaging System. The company offers a diverse range of instrumentation, consumables, and services that generate high-quality data across early discovery, translational and clinical research. Geographically, it operates in Americas; EMEA and Asia-Pacific.

行业

PHARMACEUTICAL PREPARATIONS

员工人数

389

总部

BOSTON, MA

Exchange

XNAS

官网
Source: Polygon.io
评分
竞争壁垒
竞争壁垒
44
窄护城河

基于 4 年财务数据的系统性竞争优势评估

此评估基于历史财务数据的量化分析,不构成投资建议。护城河评级可能随行业和竞争环境变化。

市场信号
估值
盈利
内部人交易
内部人备案活动

首版展示近期 SEC Forms 3、4、5 备案活动。尚未解析单笔买入/卖出交易。

加载 SEC 内部人备案数据...
超级投资者
财务健康
财务健康

资本结构

总权益$539.97M
总债务$0.00M
债务权益比0.00
现金及等价物$270.03M

现金流

经营现金流$-80.30M
自由现金流$-82.58M
自由现金流率-97.61%
P/FCF 比率-3.28
Source: Polygon.io · SEC EDGAR
股息
最新资讯
Recent News

免责声明:本站内容不构成投资建议。数据来源于SEC EDGAR和Polygon.io。过往业绩不代表未来表现。投资决策前请自行研究。